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Introduction
Shwachman-Diamond syndrome (SDS; OMIM 260400) is a rare congenital multi-systemic disorder characterized by exocrine pancreatic insufficiency, skeletal defects and bone marrow failure. [1] [2] [3] The hematological hallmark of the disease is neutropenia, which affects 88% to 98% of patients 4, 5 and represents, together with leukemic evolution, the main cause of morbidity and mortality in SDS. 1, [6] [7] [8] Other, less common manifestations are anemia, thrombocytopenia and pancytopenia. 6, 7 The disease is caused by biallelic loss of function mutations in the Shwachman-Bodian-Diamond Syndrome gene (SBDS). 9 The two most common mutations, 258+2T→C and 183-184TA→CT, result in impaired splicing and a premature stop codon, respectively, and are associated with reduced protein levels of SBDS. 9, 10 SBDS plays an essential role in ribosome biogenesis. In particular, the concerted activity of SBDS and elongation factor-like 1 (EFL1) mediates the removal of eukaryotic initiation factor 6 (eIF6) during the cytoplasmic maturation of the pre-60S subunit, allowing the formation of the 80S ribosome. [10] [11] [12] Consistent with this notion, impaired ribosome subunit joining has been demonstrated in SDS patients 12, 13 and reduced overall translation was detected in yeast models of SDS. 11 Defects in ribosome biogenesis define a group of pathologies collectively known as ribosomopathies. Causative mutations in genes linked to ribosome biogenesis have been identified in several congenital diseases including Diamond-Blackfan anemia (DBA), dyskeratosis congenita and cartilage-hair hypoplasia. While the hematopoietic system is affected in most of these conditions, leading to some degree of bone marrow failure, pronounced vulnerability of specific cell lineages discerns these disorders, with neutropenia being the specific hallmark of SDS. This reflects the central enigma in the understanding of human congenital ribosomopathies, i.e. how disruption of ribosome biogenesis, a process occurring in all tissues with a proposed generic role in protein synthesis, results in cell and tissue specific disease phenotypes.
It is thought that ribosomes, and hence the proteins related to their biogenesis, are critically important for fast cycling cells, thus leading to impaired function of hematopoietic progenitor cells, resulting in cytopenia, but this view provides no explanation for cell type specificity (neutropenia) in SDS. 14, 15 Identification of the cell types specifically affected by dysfunction of ribosomal genes will thus be critical in deciphering the underlying molecular mechanisms driving disease pathology, ultimately enabling targeted therapies. However, progress in understanding the pathophysiology of SDS is limited by the lack of a robust mammalian model faithfully recapitulating neutropenia. Deficiency of Sbds leads to embryonic lethality in full knockout mice 10, 16 and transplantation of shRNA-transduced, Sbds-deficient murine hematopoietic cells in wild type recipient mice did not result in overt neutropenia, although it impaired myeloid progenitor generation. 17 Targeting Sbds in the hematopoietic system via poly(I:C) treatment of Sbds fl/-Tg:Mx1-cre mice resulted in a severe hepatic phenotype, precluding a thorough investigation of the hematological consequences of Sbds deficiency in adult hematopoietic stem cells (HSCs). 10 Thus, in vivo targeting of Sbds in postnatal mammalian hematopoiesis remains a key challenge for the field.
The basic leucine zipper transcription factor CCAAT/Enhancer-Binding Protein α (C/EBPα) is expressed in a fraction of HSCs and throughout the myeloid lineage, [18] [19] [20] thus offering an alternative approach to target hematopoietic stem and progenitor cells and their downstream myeloid lineage progeny in adult mammals.
Here, we generated a novel mouse model of genetic Sbds deletion through targeted downregulation of the gene in Cebpa-expressing cells, resulting in profound neutropenia. We show that loss of Sbds is well tolerated by rapidly cycling myeloid progenitor cells and identify myelocytes and their downstream progeny as the cell types within the hematopoietic hierarchy critically affected by Sbds deficiency through induction of cellular stress and apoptosis, thus providing a cellular and molecular basis for neutropenia in SDS.
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Methods
Additional information is provided in the Online Supplement. 
Mice and Genotyping
Cebpa
Statistical Analysis
Unless otherwise specified, statistical analysis was performed by an unpaired, 2-tailed Student's t test or 1-way analysis of variance. All results in bar graphs are reported as mean value ± standard error of the mean.
Results
Cebpa-driven deletion of Sbds in the hematopoietic system
To address the functional consequences of Sbds deficiency in early hematopoietic progenitors, we crossed
Sbds-conditional knock-out mice, with loxP sites flanking the second exon of Sbds, 21 with Cebpa cre/+ R26 EYFP mice 19 ( Figure 1A ). In this approach, Cre-mediated deletion of Sbds exon 2 in Cebpa-expressing cells results in a frameshift and consequently generates a premature stop codon, thus mimicking the effects of the 183-184TA→CT mutation in the human disease. 9 In addition, the R26 EYFP element Figure 1A , Figure 1B ). We next compared hematopoiesis in Sbds f/f embryos with that of Cebpa cre/+ ;R26 EYFP/+ controls (hence Sbds +/+) and found that Sbds recombination was associated with overall conservation of normal hematopoietic architecture in the fetal liver ( Figure 1C ). This suggests that embryonic lethality in this model is not caused by impaired blood cell production. Figure S1 ).
Overall, the data indicates that Sbds is essential to maintain postnatal granulopoiesis and neutrophil homeostasis. Figure 3A ). The bone marrow of mice transplanted with Sbds f/f fetal liver cells was hypocellular, a common finding in SDS patients 7, 25 ( Figure Table S3 and S4) .
Sbds
Gene set enrichment analysis (GSEA) highlighted the enrichment of relatively immature hematopoietic signatures in Sbds f/f MC-MMs, whereas data sets associated with cell differentiation were enriched in controls, consistent with a defect in maturation ( Figure 4C ; Online Supplementary Table S3 ). To specifically define the stage in which myeloid differentiation is impaired, we examined the expression of transcripts encoding constituents of myeloid granules. In myeloid development, primary granules are produced in promyelocytes, whereas secondary granule production starts in myelocytes and gelatinasecontaining tertiary granules become apparent in metamyelocytes and in band cells. 29, 30 Transcript analysis showed significantly reduced expression of secondary and tertiary granule components, whereas transcripts encoding constituents of primary granules were significantly enriched, indicating that development is specifically arrested in myelocytes, consistent with flow-cytometric findings ( Figure 4D ).
To definitively establish the myelocyte as the cell type in the myeloid lineage critically depending on Sbds expression, we next performed cell cycle analysis. Myelocytes represent the last cell in myeloid differentiation capable of mitotic division 31 and cell cycle exit is a required process for terminal granulopoiesis 32 . Ki67 analysis by FACS demonstrated that c-Kit int Gr1 low cells indeed failed to exit the cell cycle, congruent with the notion that Sbds deficiency attenuates lineage progression in myelocytes ( Figure 4E , Figure 4F ). Molecularly, this failure to exit the cell cycle was associated with significant reduced expression of the transcription factor retinoic acid receptor α (RARα) and its downstream transcriptional targets Itgb2 and p27 (Cdkn1b), 33 , 34 key activators of the terminal myeloid differentiation program and cell cycle exit ( Figure 4G ). Together, the data demonstrates that loss of Sbds from hematopoietic progenitors results in failure of lineage progression specifically in myelocytes, which is associated with attenuation of myeloid differentiation signatures and cellular events. Figure   5D ). Of note, no significant p53 accumulation or apoptosis was observed in more immature progenitors (cKit + EYFP + cells).
Collectively, the findings indicate that Sbds deficiency in the myeloid lineage specifically attenuates lineage progression at the myelocyte stage through activation of cellular stress pathways and induction of p53-associated apoptosis.
Discussion
Neutropenia is the principal hematological manifestation of SDS, but the cellular and molecular mechanisms underlying this specific disease phenotype remain poorly understood. Here, we established a 1 2 Identification of the cells driving neutropenia within the Sbds-deficient hematopoietic hierarchy allowed us to begin defining the cellular and molecular events underlying neutropenia in SDS. Our study describes activation of the p53 pathway and an associated increase in apoptotic rates specifically in myelocytes and their downstream progeny. The data seems congruent with observations in human disease where an intrinsic propensity for apoptosis is seen in hematopoietic cells after 7-day culture of CD34+ cells in
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medium containing G-CSF 46 with a lack of correlation between colony numbers and apoptosis rate, indicating that the number of CFU-C is not affected in SDS patients. Activation of the p53 pathway has been suggested to represent a molecular commonality in ribosomopathies and perhaps congenital neutropenias 47 but experimental support for this view in SDS has been lacking. Our findings do not, however, exclude the possibility that other mechanisms are involved in the failure in cell cycle progression and neutropenia in SDS.
It is conceivable that the loss of function of Sbds affects the translation of specific transcription factors driving terminal myeloid differentiation, including those upstream of RARα. In particular, the mRNA of specific transcription factor isoforms may be characterized by distinct 5'-UTRs, some of them predicted to have a complex secondary structure. 48 These complex 5'-UTRs are typically associated with high demands for translation initiation factors and may thus confer particular sensitivity to conditions of translational stress. Such a mechanism of reduced translation efficiency has recently been shown to affect GATA1 protein levels in the pathogenesis of DBA. 49 Alternatively, the high and specific demand of protein synthesis and cotranslational assembly into secretory granules, which characterizes and defines myelocytes and their downstream progeny, may cause specific translational stress, resulting in activation of cellular alarm pathways and downstream events including impaired differentiation. In this context, it is interesting to note previous observations in induced pluripotent stem cell models of SDS, indicating granule abnormalities in pancreatic and myeloid cells, 50 and in a mouse model of pancreatic-specific Sbds deficiency, showing reduced in vivo zymogen granule formation in acinar cells, 21 perhaps pointing towards impaired secretory granule maturation as a common mechanism underlying tissue specificity in SDS. 50 Our current model will allow the interrogation of these potential mechanisms which is ultimately anticipated to result in novel, targeted therapeutic strategies for SDS.
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Supplemental methods
Peripheral Blood Measurements
Peripheral blood was collected by submandibular bleeding in K2EDTA-coated microtainers (BD).
Hematological parameters were analyzed using a Vet ABC counter (Scil Animal Care).
Flow Cytometry
Bone marrow cells were isolated as previously reported. 
Bone Marrow Morphology
For morphological studies, cytospin preparations were obtained from 5x10 5 bone marrow cells per transplanted mouse and stained with May-Grünwald-Giemsa as previously reported. Table S1 and run on a Table S1 . Oligonucleotide primers used in this study. 
